Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.

Anthony C Wood; Ariel Perez Perez; Brian Arciola; Kedar N Patel; Grace Johnson; Elizabeth DiMaggio; Christina A Bachmeier; Kayla Reid; Salvatore Carallo; Melanie H Vargas; Rawan Faramand; Julio C Chavez; Bijal Shah; Sameh Gaballa; Farhad Khimani; Hany Elmariah; Taiga Nishihori; Aleksandr Lazaryan; Ciara Freeman; Marco L Davila; Frederick L Locke; Rahul Mhaskar; Claude Bassil; Michael D Jain

Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.

Anthony C Wood, Ariel Perez Perez, Brian Arciola, Kedar N Patel, Grace Johnson, Elizabeth DiMaggio, Christina A Bachmeier, Kayla Reid, Salvatore Carallo, Melanie H Vargas, Rawan Faramand, Julio C Chavez, Bijal Shah, Sameh Gaballa, Farhad Khimani, Hany Elmariah, Taiga Nishihori, Aleksandr Lazaryan, Ciara Freeman, Marco L DavilaFrederick L Locke, Rahul Mhaskar, Claude Bassil, Michael D Jain

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T cell therapies. We evaluated the outcomes of patients with RI receiving standard of care (SOC) CAR T cell therapy for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this retrospective, single-center cohort study of patients with R/R DLBCL treated with SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after 2 or more prior lines of therapy, renal and survival outcomes were compared based on RI and fludarabine dose reduction (DR) status. RI was defined by an estimated glomerular filtration rate/min/1.73 m

Original language	American English
Journal	Transplant Cell Ther
Volume	28
State	Published - Dec 1 2022

Keywords

Acute Kidney Injury
Adoptive
Antigens
CD19
Cell- and Tissue-Based Therapy
Chimeric Antigen
Chronic
Cohort Studies
Cytokine Release Syndrome
Cytokines
Diffuse
Humans
Immunotherapy
Kidney
Kidney Failure
Large B-Cell
Lymphoma
Receptors
Renal Dialysis
Retrospective Studies
United States

Disciplines

Medical Education
Medicine and Health Sciences

Access to Document

https://pubmed.ncbi.nlm.nih.gov/36174934/

Cite this

Wood, A. C., Perez, A. P., Arciola, B., Patel, K. N., Johnson, G., DiMaggio, E., Bachmeier, C. A., Reid, K., Carallo, S., Vargas, M. H., Faramand, R., Chavez, J. C., Shah, B., Gaballa, S., Khimani, F., Elmariah, H., Nishihori, T., Lazaryan, A., Freeman, C., ... Jain, M. D. (2022). Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther, 28. https://pubmed.ncbi.nlm.nih.gov/36174934/

Wood, AC, Perez, AP, Arciola, B, Patel, KN, Johnson, G, DiMaggio, E, Bachmeier, CA, Reid, K, Carallo, S, Vargas, MH, Faramand, R, Chavez, JC, Shah, B, Gaballa, S, Khimani, F, Elmariah, H, Nishihori, T, Lazaryan, A, Freeman, C, Davila, ML, Locke, FL, Mhaskar, R, Bassil, C & Jain, MD 2022, 'Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.', Transplant Cell Ther, vol. 28. <https://pubmed.ncbi.nlm.nih.gov/36174934/>

@article{46a245fe2b674eb29e2bbc7c6cfc3faa,

title = "Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.",

abstract = " Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T cell therapies. We evaluated the outcomes of patients with RI receiving standard of care (SOC) CAR T cell therapy for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this retrospective, single-center cohort study of patients with R/R DLBCL treated with SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after 2 or more prior lines of therapy, renal and survival outcomes were compared based on RI and fludarabine dose reduction (DR) status. RI was defined by an estimated glomerular filtration rate/min/1.73 m",

keywords = "Acute Kidney Injury, Adoptive, Antigens, CD19, Cell- and Tissue-Based Therapy, Chimeric Antigen, Chronic, Cohort Studies, Cytokine Release Syndrome, Cytokines, Diffuse, Humans, Immunotherapy, Kidney, Kidney Failure, Large B-Cell, Lymphoma, Receptors, Renal Dialysis, Retrospective Studies, United States",

author = "Wood, \{Anthony C\} and Perez, \{Ariel Perez\} and Brian Arciola and Patel, \{Kedar N\} and Grace Johnson and Elizabeth DiMaggio and Bachmeier, \{Christina A\} and Kayla Reid and Salvatore Carallo and Vargas, \{Melanie H\} and Rawan Faramand and Chavez, \{Julio C\} and Bijal Shah and Sameh Gaballa and Farhad Khimani and Hany Elmariah and Taiga Nishihori and Aleksandr Lazaryan and Ciara Freeman and Davila, \{Marco L\} and Locke, \{Frederick L\} and Rahul Mhaskar and Claude Bassil and Jain, \{Michael D\}",

note = "Wood, A. C., Perez, A. P., Arciola, B., Patel, K., Johnson, G., DiMaggio, E., Bachmeier, C. A., Reid, K., Carallo, S., Vargas, M. H., Faramand, R., Chavez, J. C., Shah, B., Gaballa, S., Khimani, F., Elmariah, H., Nishihori, T., Lazaryan, A., Freeman, C., Davila, M. L., … Jain, M. D. (2022). Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplantation and cellular therapy, 28(12), 829.e1–829.e8. https://doi.org/10.1016/j.jtct.2022.09.009",

year = "2022",

month = dec,

day = "1",

language = "American English",

volume = "28",

journal = "Transplant Cell Ther",

}

TY - JOUR

T1 - Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.

AU - Wood, Anthony C

AU - Perez, Ariel Perez

AU - Arciola, Brian

AU - Patel, Kedar N

AU - Johnson, Grace

AU - DiMaggio, Elizabeth

AU - Bachmeier, Christina A

AU - Reid, Kayla

AU - Carallo, Salvatore

AU - Vargas, Melanie H

AU - Faramand, Rawan

AU - Chavez, Julio C

AU - Shah, Bijal

AU - Gaballa, Sameh

AU - Khimani, Farhad

AU - Elmariah, Hany

AU - Nishihori, Taiga

AU - Lazaryan, Aleksandr

AU - Freeman, Ciara

AU - Davila, Marco L

AU - Locke, Frederick L

AU - Mhaskar, Rahul

AU - Bassil, Claude

AU - Jain, Michael D

N1 - Wood, A. C., Perez, A. P., Arciola, B., Patel, K., Johnson, G., DiMaggio, E., Bachmeier, C. A., Reid, K., Carallo, S., Vargas, M. H., Faramand, R., Chavez, J. C., Shah, B., Gaballa, S., Khimani, F., Elmariah, H., Nishihori, T., Lazaryan, A., Freeman, C., Davila, M. L., … Jain, M. D. (2022). Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplantation and cellular therapy, 28(12), 829.e1–829.e8. https://doi.org/10.1016/j.jtct.2022.09.009

PY - 2022/12/1

Y1 - 2022/12/1

N2 - Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T cell therapies. We evaluated the outcomes of patients with RI receiving standard of care (SOC) CAR T cell therapy for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this retrospective, single-center cohort study of patients with R/R DLBCL treated with SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after 2 or more prior lines of therapy, renal and survival outcomes were compared based on RI and fludarabine dose reduction (DR) status. RI was defined by an estimated glomerular filtration rate/min/1.73 m

AB - Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T cell therapies. We evaluated the outcomes of patients with RI receiving standard of care (SOC) CAR T cell therapy for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this retrospective, single-center cohort study of patients with R/R DLBCL treated with SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after 2 or more prior lines of therapy, renal and survival outcomes were compared based on RI and fludarabine dose reduction (DR) status. RI was defined by an estimated glomerular filtration rate/min/1.73 m

KW - Acute Kidney Injury

KW - Adoptive

KW - Antigens

KW - CD19

KW - Cell- and Tissue-Based Therapy

KW - Chimeric Antigen

KW - Chronic

KW - Cohort Studies

KW - Cytokine Release Syndrome

KW - Cytokines

KW - Diffuse

KW - Humans

KW - Immunotherapy

KW - Kidney

KW - Kidney Failure

KW - Large B-Cell

KW - Lymphoma

KW - Receptors

KW - Renal Dialysis

KW - Retrospective Studies

KW - United States

UR - https://scholarlyworks.lvhn.org/select-program/477

UR - https://pubmed.ncbi.nlm.nih.gov/36174934/

M3 - Article

VL - 28

JO - Transplant Cell Ther

JF - Transplant Cell Ther

ER -

Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.

Abstract

Keywords

Disciplines

Access to Document

Other files and links

Cite this